Market Overview

NanoString Technologies Announces Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock

Share:

SEATTLE, Aug. 13, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the underwriters of its previously announced underwritten public offering have exercised their option to purchase an additional of 600,000 shares of its common stock. The closing of the option exercise occurred on August 13, 2018. Net proceeds from the offering of an aggregate of 4,600,000 shares at a per share price to the public of $12.50 were approximately $53.9 million. NanoString intends to use the net proceeds of the offering for the development and launch of its Digital Spatial Profiling platform, the continued commercialization of its portfolio of nCounter-based products, and for general corporate purposes and working capital.

J.P. Morgan and UBS Investment Bank acted as joint book-running managers for the offering. Baird acted as lead manager for the offering.

A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on August 30, 2017, amended on September 11, 2017 and declared effective by the SEC on September 14, 2017.  The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.  A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, 25th floor, New York, NY 10019, or by phone at 888-827-7275 or by email at ol-prospectus-request@ubs.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contact   
Douglas Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

Primary Logo

View Comments and Join the Discussion!